查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1580875

肌張力障礙治療藥物市場：按藥物類型、給藥方法、最終用戶分類 - 全球預測 2025-2030

Dystonia Drugs Market by Drug Type (Anticholinergic Drugs, Botulinum Toxins, Dopaminergic Drugs), Mode of Administration (Injectable, Oral), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肌張力障礙治療藥物市場價值為8.0617億美元，預計到2024年將達到8.5148億美元，複合年成長率為5.81%，到2030年將達到11.9716億美元。

肌張力障礙治療市場包括旨在治療肌張力失調的藥物和治療性介入，肌張力失調是一種運動障礙，其特徵是不自主的肌肉收縮，導致重複運動和異常姿勢。肌張力障礙治療藥物的需求源於肌肌張力不全症對患者生活品質的重大影響，這需要有效的治療來緩解症狀。這些藥物用於治療成人和兒童患者的各種肌張力不全症，包括頸部肌肌張力不全症、眼瞼痙攣和整體肌張力不全症。最終用途範圍包括醫院、專科診所和居家照護機構等醫療保健提供者。

主要市場統計
基準年[2023] 80617萬美元
預測年份 [2024] 85148萬美元
預測年份 [2030] 11.9716億美元
複合年成長率（%） 5.81%

影響市場的主要成長要素包括肌張力不全症盛行率的增加、對神經系統疾病理解的重大發展以及新療法的開發。尤其是生技藥品和肉毒桿菌毒素，因其在控制症狀、同時最大限度地減少副作用方面的有效性和精確性而越來越受歡迎。新的商機存在於生物技術領域，該領域正在創新針對肌張力不全症病理學分子層面的基因療法和精準醫學方法。生技公司和學術機構之間的策略聯盟可以帶來重大進展。

然而，市場成長面臨著治療成本高、一般醫療保健提供者缺乏理解以及嚴格的法規環境等挑戰。此外，某些治療方法，例如肉毒桿菌毒素，需要高度專業化的管理，需要培訓和專業知識，而這些培訓和專業知識並不總是容易獲得，特別是在發展中地區。

創新和研究的機會包括開發針對肌張力不全症特定神經途徑的小分子，以及使用人工智慧來實現更好的診斷和個人化治療計劃。此外，對非藥物干預措施（例如深部腦部刺激和物理治療）的研究可以補充藥物治療並提供整體治療選擇。

了解肌張力障礙治療藥物市場作為更廣泛的神經系統疾病治療中的利基市場的微妙本質對於獲得市場佔有率和預測未來趨勢至關重要。公司應專注於醫療保健提供者的教育和意識計劃，以更好地向從業者介紹肌張力障礙治療，並讓先進的治療選擇更廣泛地提供。

市場動態：揭示快速發展的肌張力障礙治療市場的關鍵市場洞察

供需的動態交互作用正在改變肌張力障礙治療藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 運動障礙的盛行率不斷上升，導致全球對肌張力障礙治療藥物的需求增加
    • 醫學研究和生物技術的不斷進步影響肌張力障礙治療選擇
    • 醫療保健支出的增加和可近性的改善推動了肌張力障礙治療藥物的需求
    • 提高患者認知並改善診斷技術以提高肌張力不全症的早期診斷率
  • 市場限制因素
    • 嚴格的監管要求影響肌張力障礙治療的核准流程
    • 缺乏認知和正確診斷限制了肌張力不全症患者的有效治療
  • 市場機會
    • 針對肌張力不全症的根本原因開發新的治療藥物
    • 透過將個人化醫療整合到肌張力障礙治療中來改善患者的治療效果
    • 擴大新興市場的醫療基礎設施為肌張力障礙治療藥物製造商創造了新的機會
  • 市場挑戰
    • 嚴格的監管要求和核准流程阻礙了新的肌張力障礙治療的推出
    • 肌張力不全症失調罕見導致的臨床試驗挑戰影響藥物開發效率

波特的五力：駕馭肌張力障礙治療藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肌張力障礙治療市場的外在影響

外在宏觀環境因素在塑造肌張力障礙治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肌張力障礙治療藥物市場的競爭狀況

對肌張力障礙治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣肌肌張力障礙治療市場供應商的績效評估

FPNV 定位矩陣是評估肌張力障礙治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製肌張力障礙治療藥物市場的成功之路

對於想要加強在全球市場的影響力的公司來說，對肌張力障礙治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 運動障礙的日益流行正在推動全球肌張力障礙治療的需求
      • 醫學研究和生物技術的進步影響肌張力不全症的治療選擇
      • 醫療成本的上升和獲取的便利性推動了肌張力障礙治療藥物的需求
      • 提高患者意識提升和診斷技術將改善肌張力不全症的早期診斷
    • 抑制因素
      • 嚴格的監管要求影響肌張力障礙治療的核准流程
      • 缺乏認知和正確診斷限制了肌張力不全症患者的有效治療
    • 機會
      • 開發針對肌張力不全症根本原因的新治療藥物
      • 透過將個人化醫療方法整合到肌張力障礙治療中來改善患者的治療效果
      • 擴大新興市場的醫療保健基礎設施為肌張力障礙治療藥物製造商創造了新的機會
    • 任務
      • 嚴格的監管要求和核准流程阻礙了肌張力不全症新治療方法的推出
      • 肌張力不全症失調罕見導致的臨床試驗挑戰影響藥物開發效率
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肌張力障礙治療藥物市場（依藥物類型）

  • 抗膽鹼能藥物
  • 肉毒桿菌毒素
  • 多巴胺促效劑
  • 肌肉鬆弛劑

第7章依管理方式肌張力障礙治療藥物市場

  • 可注射的
  • 口服

第8章肌張力障礙治療藥物市場：依最終使用者分類

  • 診所
  • 家庭護理設置
  • 醫院

第9章 北美和南美肌肌張力障礙治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區肌張力障礙治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲肌張力障礙治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Evolus, Inc.
  • Galderma SA
  • GlaxoSmithKline PLC
  • Ipsen Biopharmaceuticals, Inc.
  • Medytox
  • Novartis AG
  • Revance Therapeutics, Inc.
  • Sanofi SA
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Limited
  • Uniprix
Product Code: MRR-92533CCD3ABC

The Dystonia Drugs Market was valued at USD 806.17 million in 2023, expected to reach USD 851.48 million in 2024, and is projected to grow at a CAGR of 5.81%, to USD 1,197.16 million by 2030.

The dystonia drugs market encompasses the pharmaceutical products and therapeutic interventions designed to treat dystonia, a movement disorder characterized by involuntary muscle contractions that cause repetitive movements or abnormal postures. The necessity for dystonia drugs stems from the significant impact of the disorder on patients' quality of life, necessitating effective management to alleviate symptoms. Applications of these drugs span across various forms of dystonia, including cervical dystonia, blepharospasm, and general dystonia, targeting both adults and pediatric patients. End-use scope includes healthcare providers such as hospitals, specialty clinics, and homecare settings.

KEY MARKET STATISTICS
Base Year [2023] USD 806.17 million
Estimated Year [2024] USD 851.48 million
Forecast Year [2030] USD 1,197.16 million
CAGR (%) 5.81%

Key growth factors influencing the market include increasing prevalence of dystonia, advancements in neurological disorder understanding, and development of novel therapeutics. Biologics and botulinum toxins are particularly gaining traction due to their efficacy and precision in managing symptoms with minimal side effects. Emerging opportunities lie in the biotechnology sector, which is innovating gene therapies and precision medicine approaches aimed at the molecular level of dystonia pathology. Strategic partnerships between biotech firms and academic institutions could yield significant advancements.

However, market growth faces challenges such as high treatment costs, limited understanding among general healthcare providers, and stringent regulatory environments. Additionally, the need for highly specialized administration of certain therapies like botulinum toxins necessitates training and expertise that aren't always readily available, particularly in developing regions.

Opportunities for innovation and research include the development of small molecules targeting specific neurological pathways involved in dystonia, and leveraging artificial intelligence for better diagnosis and personalized treatment plans. Furthermore, research into non-pharmacological interventions, such as deep brain stimulation and physical therapies, can complement drug therapies and provide holistic treatment options.

Understanding the nuanced nature of the dystonia drugs market as a niche within the broader neurological disorder therapy landscape is crucial for capturing market share and anticipating future trends. Companies should focus on educating healthcare providers and investing in awareness programs to better inform practitioners about dystonia treatments and foster wider adoption of advanced therapeutic options.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dystonia Drugs Market

The Dystonia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of movement disorders leading to higher demand for dystonia drugs worldwide
    • Rising advancements in medical research and biotechnology impacting dystonia treatment options
    • Growing healthcare expenditure and accessibility driving the demand for dystonia therapeutics
    • Enhanced patient awareness and improved diagnostic techniques boosting early dystonia diagnosis rates
  • Market Restraints
    • Stringent regulatory requirements affecting the approval process for dystonia drugs
    • Lack of awareness and proper diagnosis limiting the effective treatment of dystonia patients
  • Market Opportunities
    • Development of novel therapeutic agents targeting underlying causes of dystonia
    • Integration of personalized medicine approaches for dystonia treatment to improve patient outcomes
    • Expansion of healthcare infrastructure in emerging markets creating new opportunities for dystonia drug manufacturers
  • Market Challenges
    • Stringent regulatory requirements and approval processes hindering the introduction of new dystonia treatments
    • Challenges in clinical trials due to the rarity of dystonia affecting drug development efficiency

Porter's Five Forces: A Strategic Tool for Navigating the Dystonia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dystonia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dystonia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dystonia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dystonia Drugs Market

A detailed market share analysis in the Dystonia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dystonia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dystonia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dystonia Drugs Market

A strategic analysis of the Dystonia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dystonia Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Cipla Limited, Dr. Reddy's Laboratories, Evolus, Inc., Galderma SA, GlaxoSmithKline PLC, Ipsen Biopharmaceuticals, Inc., Medytox, Novartis AG, Revance Therapeutics, Inc., Sanofi S.A., Sihuan Pharmaceutical Holdings Group Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, and Uniprix.

Market Segmentation & Coverage

This research report categorizes the Dystonia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anticholinergic Drugs, Botulinum Toxins, Dopaminergic Drugs, and Muscle Relaxants.
  • Based on Mode of Administration, market is studied across Injectable and Oral.
  • Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of movement disorders leading to higher demand for dystonia drugs worldwide
      • 5.1.1.2. Rising advancements in medical research and biotechnology impacting dystonia treatment options
      • 5.1.1.3. Growing healthcare expenditure and accessibility driving the demand for dystonia therapeutics
      • 5.1.1.4. Enhanced patient awareness and improved diagnostic techniques boosting early dystonia diagnosis rates
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory requirements affecting the approval process for dystonia drugs
      • 5.1.2.2. Lack of awareness and proper diagnosis limiting the effective treatment of dystonia patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel therapeutic agents targeting underlying causes of dystonia
      • 5.1.3.2. Integration of personalized medicine approaches for dystonia treatment to improve patient outcomes
      • 5.1.3.3. Expansion of healthcare infrastructure in emerging markets creating new opportunities for dystonia drug manufacturers
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and approval processes hindering the introduction of new dystonia treatments
      • 5.1.4.2. Challenges in clinical trials due to the rarity of dystonia affecting drug development efficiency
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dystonia Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anticholinergic Drugs
  • 6.3. Botulinum Toxins
  • 6.4. Dopaminergic Drugs
  • 6.5. Muscle Relaxants

7. Dystonia Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Dystonia Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals

9. Americas Dystonia Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Dystonia Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Dystonia Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Cipla Limited
  • 3. Dr. Reddy's Laboratories
  • 4. Evolus, Inc.
  • 5. Galderma SA
  • 6. GlaxoSmithKline PLC
  • 7. Ipsen Biopharmaceuticals, Inc.
  • 8. Medytox
  • 9. Novartis AG
  • 10. Revance Therapeutics, Inc.
  • 11. Sanofi S.A.
  • 12. Sihuan Pharmaceutical Holdings Group Ltd.
  • 13. Sun Pharmaceutical Industries Ltd.
  • 14. Teva Pharmaceutical Industries Limited
  • 15. Uniprix

LIST OF FIGURES

  • FIGURE 1. DYSTONIA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DYSTONIA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DYSTONIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DYSTONIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DYSTONIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DYSTONIA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DYSTONIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DYSTONIA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY ANTICHOLINERGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY BOTULINUM TOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DOPAMINERGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MUSCLE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. DYSTONIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. DYSTONIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023